Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Camm John) "

Sökning: WFRF:(Camm John)

  • Resultat 1-10 av 67
  • [1]234567Nästa
Sortera/gruppera träfflistan
  • Kirchhof, Paulus, et al. (författare)
  • Comprehensive risk reduction in patients with atrial fibrillation : emerging diagnostic and therapeutic options - a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference
  • 2012
  • Ingår i: Europace. - 1099-5129 .- 1532-2092. ; 14:1, s. 8-27
  • Forskningsöversikt (refereegranskat)abstract
    • While management of atrial fibrillation (AF) patients is improved by guideline-conform application of anticoagulant therapy, rate control, rhythm control, and therapy of accompanying heart disease, the morbidity and mortality associated with AF remain unacceptably high. This paper describes the proceedings of the 3rd Atrial Fibrillation NETwork (AFNET)/European Heart Rhythm Association (EHRA) consensus conference that convened over 60 scientists and representatives from industry to jointly discuss emerging therapeutic and diagnostic improvements to achieve better management of AF patients. The paper covers four chapters: (i) risk factors and risk markers for AF; (ii) pathophysiological classification of AF; (iii) relevance of monitored AF duration for AF-related outcomes; and (iv) perspectives and needs for implementing better antithrombotic therapy. Relevant published literature for each section is covered, and suggestions for the improvement of management in each area are put forward. Combined, the propositions formulate a perspective to implement comprehensive management in AF.
  • Camm, A. John, et al. (författare)
  • Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial
  • 2012
  • Ingår i: Europace. - : Oxford University Press. - 1532-2092. ; 14:6, s. 804-809
  • Tidskriftsartikel (refereegranskat)abstract
    • Vernakalant is a novel, relatively atrial-selective antiarrhythmic agent for conversion of atrial fibrillation (AF) to sinus rhythm. This study examined the safety and efficacy of vernakalant in converting atrial flutter (AFL) to sinus rhythm. This was a phase 2/3, randomized, double-blind, placebo-controlled trial. Adults with AFL received either a 10 min infusion of 3.0 mg/kg vernakalant (n 39) or placebo (n 15). If AFL or AF persisted at the end of a 15 min observation period, a second 10 min infusion of 2.0 mg/kg vernakalant or placebo was administered. The primary efficacy outcome was the proportion of patients who had treatment-induced conversion of AFL to sinus rhythm for a minimum duration of 1 min within 90 min after the start of the first infusion. No patient in the placebo group met the primary outcome. Only one patient receiving vernakalant (1 of 39, 3) converted to sinus rhythm. A reduced mean absolute ventricular response rate occurred within 50 min in patients receiving vernakalant (mean change from baseline 8.2 b.p.m.) vs. patients receiving placebo (0.2 b.p.m.) (P 0.037). A post-hoc analysis revealed that vernakalant increased AFL cycle length by an average of 55 ms, whereas the AFL cycle length was unchanged in the placebo group (P 0.001). There was no occurrence of 1 : 1 atrio-ventricular conduction. Dysgeusia and sneezing were the most common treatment-related adverse events, consistent with previous reports. Vernakalant did not restore sinus rhythm in patients with AFL. Vernakalant modestly slowed AFL and ventricular response rates, and was well tolerated.
  • Camm, A John, et al. (författare)
  • XANTUS : a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation.
  • 2016
  • Ingår i: European Heart Journal. - 0195-668X .- 1522-9645. ; 37:14, s. 1145-53
  • Tidskriftsartikel (refereegranskat)abstract
    • AIMS: Although non-vitamin K antagonist oral anticoagulants are recommended for stroke prevention in patients with non-valvular atrial fibrillation (NVAF) based on clinical trial results, there is a need for safety and efficacy data from unselected patients in everyday clinical practice. XANTUS investigated the safety and efficacy of the Factor Xa inhibitor rivaroxaban in routine clinical use in the NVAF setting.METHODS AND RESULTS: Consecutive consenting patients with NVAF newly started on rivaroxaban were eligible and were followed up at ∼3-month intervals for 1 year, or for at least 30 days after permanent discontinuation. All adverse events (AEs) were recorded as AEs or serious AEs; major outcomes (including major bleeding, symptomatic thromboembolic events [stroke, systemic embolism, transient ischaemic attack, and myocardial infarction], and all-cause death) were centrally adjudicated. There were 6784 patients treated with rivaroxaban at 311 centres in Europe, Israel, and Canada. Mean patient age was 71.5 years (range 19-99), 41% were female, and 9.4% had documented severe or moderate renal impairment (creatinine clearance <50 mL/min). The mean CHADS2 and CHA2DS2-VASc scores were 2.0 and 3.4, respectively; 859 (12.7%) patients had a CHA2DS2-VASc score of 0 or 1. The mean treatment duration was 329 days. Treatment-emergent major bleeding occurred in 128 patients (2.1 events per 100 patient-years), 118 (1.9 events per 100 patient-years) died, and 43 (0.7 events per 100 patient-years) suffered a stroke.CONCLUSION: XANTUS is the first international, prospective, observational study to describe the use of rivaroxaban in a broad NVAF patient population. Rates of stroke and major bleeding were low in patients receiving rivaroxaban in routine clinical practice.TRIAL REGISTRATION NUMBER: Clinicaltrials.gov: NCT01606995.
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 67
  • [1]234567Nästa
Typ av publikation
tidskriftsartikel (58)
forskningsöversikt (7)
bokkapitel (2)
Typ av innehåll
refereegranskat (65)
övrigt vetenskapligt (2)
Camm, A. John (41)
Kirchhof, Paulus (27)
Blomström-Lundqvist, ... (24)
Lip, Gregory Y H (22)
Camm, John (21)
Heidbuchel, Hein (17)
visa fler...
Zamorano, Jose Luis (16)
Priori, Silvia G (16)
De Caterina, Raffael ... (15)
Tendera, Michal (14)
Dean, Veronica (14)
Hindricks, Gerhard (14)
Vahanian, Alec (14)
Sechtem, Udo (14)
Funck-Brentano, Chri ... (14)
Widimsky, Petr (13)
Filippatos, Gerasimo ... (13)
Goette, Andreas (12)
Bax, Jeroen (12)
Dickstein, Kenneth (11)
Vardas, Panos (11)
Kuck, Karl-Heinz (11)
Silber, Sigmund (11)
Verhamme, Peter (10)
Sinnaeve, Peter (10)
Calkins, Hugh (10)
Schotten, Ulrich (10)
Atar, Dan (9)
Auricchio, Angelo (9)
Kristensen, Steen Da ... (9)
Van Gelder, Isabelle ... (9)
Crijns, Harry (9)
Boriani, Giuseppe (8)
Oto, Ali (8)
Cappato, Riccardo (8)
Lewalter, Thorsten (8)
Le Heuzey, Jean-Yves (8)
Hacke, Werner (7)
Alings, Marco (7)
Oldgren, Jonas, 1964 ... (7)
Potpara, Tatjana S (7)
Oldgren, Jonas (6)
Di Mario, Carlo (6)
Blomstrom-Lundqvist, ... (6)
De Backer, Guy (6)
Fagard, Robert (6)
Diener, Hans-Christo ... (6)
Capucci, Alessandro (6)
Al-Attar, Nawwar (6)
Aliot, Etienne (6)
visa färre...
Uppsala universitet (46)
Lunds universitet (9)
Göteborgs universitet (7)
Karolinska Institutet (5)
Umeå universitet (3)
Linköpings universitet (2)
visa fler...
Kungliga Tekniska Högskolan (1)
Örebro universitet (1)
visa färre...
Engelska (61)
Italienska (3)
Polska (2)
Portugisiska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (39)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy